|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0032207,
umls-concept:C0032529,
umls-concept:C0205179,
umls-concept:C0268138,
umls-concept:C0332293,
umls-concept:C0684249,
umls-concept:C1333356,
umls-concept:C1366475,
umls-concept:C1514474,
umls-concept:C1516213,
umls-concept:C1705972
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2004-6-30
|
|
pubmed:abstractText |
Platinum agents cause DNA cross-linking and oxidative damage. Genetic polymorphisms of DNA repair genes are associated with differential DNA repair activity and may explain interindividual differences in overall survival after therapy with platinum agents for non-small-cell lung cancer (NSCLC).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2594-601
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15173214-Adult,
pubmed-meshheading:15173214-Aged,
pubmed-meshheading:15173214-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15173214-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15173214-Cisplatin,
pubmed-meshheading:15173214-DNA Damage,
pubmed-meshheading:15173214-DNA Helicases,
pubmed-meshheading:15173214-DNA Repair,
pubmed-meshheading:15173214-DNA-Binding Proteins,
pubmed-meshheading:15173214-Female,
pubmed-meshheading:15173214-Humans,
pubmed-meshheading:15173214-Lung Neoplasms,
pubmed-meshheading:15173214-Male,
pubmed-meshheading:15173214-Middle Aged,
pubmed-meshheading:15173214-Oxidative Stress,
pubmed-meshheading:15173214-Polymerase Chain Reaction,
pubmed-meshheading:15173214-Polymorphism, Genetic,
pubmed-meshheading:15173214-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:15173214-Prognosis,
pubmed-meshheading:15173214-Prospective Studies,
pubmed-meshheading:15173214-Proteins,
pubmed-meshheading:15173214-Survival Analysis,
pubmed-meshheading:15173214-Transcription Factors,
pubmed-meshheading:15173214-Xeroderma Pigmentosum Group D Protein
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
|
|
pubmed:affiliation |
Department of Medicine, Massachusetts General Hospital, Boston, MA USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
